Navigation Links
Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics' Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
Date:1/31/2011

DURHAM, N.C., Jan. 31, 2011 /PRNewswire/ -- Argos Therapeutics announced today that interleukin (IL)-12 secretion can predict the potency of the company's Arcelis™ dendritic cell (DC) immunotherapy and can be used as a potency marker in a Phase 3 clinical trial testing the company's lead product, AGS-003, in metastatic renal cell carcinoma (mRCC). In vitro results published in the Journal of Immunotherapy demonstrate that the potency of mature CD40L RNA electroporated DCs correlates with IL-12 secretion by tracking the multifunctional CD8(+)/CD28(+) memory T-cell responses.

"The dependence of AGS-003-induced memory cytotoxic T lymphocytes on IL-12 secretion from DCs makes it an attractive marker for DC potency," said Charles Nicolette, Ph.D., chief scientific officer and vice president of research and development of Argos. "Using IL-12 secretion as a potency marker is highly relevant to AGS-003 since it is directly linked to the mechanism of action and it is equally relevant to other Arcelis products such as AGS-004 for HIV."

Jeff Abbey, president and chief executive officer of Argos, added, "Identifying an effective potency marker for our upcoming Phase 3 clinical trial in mRCC is a significant step in the advancement of our pipeline. We are in the process of securing funding to begin the trial by mid-2011. Our Arcelis HIV program is currently being tested in a Phase 2b study co-funded by the NIH."

Electroporation of mature DCs with RNA-encoding CD40L greatly enhances the production of IL-12, a proinflammatory cytokine necessary for the induction of T-cell immunity. In vitro results presented in the Journal of Immunotherapy reveal a correlation between the priming of CD28(+) antigen-reactive effector memory CTL displaying three or four simultaneous effector functions and the quantity of IL-12 produced by post-maturation RNA electroporated DC. By using multiparameter flow cyt
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Interleukin Genetics Reports Third Quarter 2010 Financial Results
2. Interleukin Genetics Moves Trading of Stock to OTCQB Marketplace
3. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2010 Results
4. Interleukin Genetics, Inc. Announces Conference Call to Discuss First Quarter 2010 Results
5. NYSE Amex Provides Interleukin Genetics, Inc. Extension To Meet Continued Listing Standards
6. Interleukin Genetics to Raise $5.3 Million in Registered Direct Offering
7. Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis
8. Interleukin Genetics, Inc. Announces Positive Results from Clinical Study Evaluating Genetic Tests Impact on Weight Loss
9. Interleukin Genetics Presents Research Linking Vertebral Fractures to Gene Variations in Asian Women With Osteoporosis
10. Interleukin Genetics and Geisinger to Collaborate on Genetic Tests to Predict Weight Loss Success
11. Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 20, 2013  Hill-Rom Holdings, Inc. (NYSE: ... presentation at the 38 th Annual Deutsche Bank ... on May 30, 2013, at 1:30 p.m. EDT. ... are invited to listen to the live discussion via ... it directly at http://www.media-server.com/m/p/f7bj3q84 . A recorded replay ...
(Date:5/20/2013)...  Echo Pharma Acquisition Limited ("Royalty Pharma") today announced, ... (the "Announcement"), a firm intention to increase its offer ... to $12.50 per share in cash.  The increased offer ... due diligence.  The $1.00 per share net cash right ... to waive down the Acceptance Threshold for the increased ...
(Date:5/20/2013)... Sequent Medical, Inc. announced today that it ... family of WEB ® Aneurysm Embolization Devices, and ... in select neurovascular centers in Europe.  The SL family ... enable physicians to treat a broader range of aneurysms ... are made possible by further advancement of Sequent Medical,s ...
Breaking Medicine Technology:Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 2Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 4Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 5Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 6Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 7Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 8Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 9Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 10Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 11Sequent Medical, Inc. Launches New SL Family of WEB Aneurysm Embolization Devices 2
... pleased to announce the publication of a new syndicated ... report covers the use of biologics for the treatment ... quarterly series, focuses on current and future use of ... of the key brands, barriers to broader usage, sales ...
... Nov. 2, 2010 Cypin Production, a leader in ... and China, is pleased to announce the already-high interest ... Strategies and Partnership Models for R&D Success". ... at the Hub Cira Centre in Philadelphia, is being ...
Cached Medicine Technology:Rheumatoid Arthritis Patient Share of Actemra Projected to Exceed Patient Share of Cimzia and Simponi Among the Medicare Population 2Cypin Production Announces Launch of U.S./China BioPharma Conference: 2
(Date:5/20/2013)... Mombo from Comfort & Harmony ... US Lactation Consultant Association (USLCA) May 2nd – 5th. ... other health professionals. , The USLCA annual conference ... discover and learn about the latest trends in lactation. ... nursing pillows, which new mothers use to help support ...
(Date:5/20/2013)... 2013 Mirena IUD lawsuit ... litigation recently established in U.S. District Court, Southern District ... to court records, the litigation’s first Status Conference was ... Plaintiff’s leadership positions were discussed. So far, at ... District of New York, all of which allege that ...
(Date:5/20/2013)... Co-founder of Atlanta SEO company EverSpark Interactive, ... 5th International INVEST Domaining & Internet Marketing Conference in ... and independent individuals from around the world to discuss ... The 2013 conference will take place at the Mexico ... to 21. A networking city tour day is on ...
(Date:5/20/2013)... May 20, 2013 Nearly 20 percent of kidneys ... are refused for transplant due to factors ranging from ... units to the organ going too long without blood ... these organs could be "recycled" to help solve the ... Forest Baptist Medical Center and colleagues, reporting in the ...
(Date:5/20/2013)... 2013 Horizon NJ Health, New Jersey’s ... that it has earned a Commendable Accreditation status ... NJ Health is a wholly owned subsidiary of Horizon ... NCQA Health Plan Accreditation is a nationally recognized program ... health plans provide to their members. Health Plan Accreditation ...
Breaking Medicine News(10 mins):Health News:Comfort & Harmony™ Exhibited mombo™ Nursing Pillow at USLCA’s First Inaugural Conference 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 3Health News:EverSpark CEO to be Keynote Speaker at 5th International INVEST Domaining & Internet Marketing Conference in Mexico City 2Health News:Study suggests new source of kidneys for transplant 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 3
... ,Kick Butts Day, at 11 a.m. in Kettering, ... leaders from Ohio will hold a press conference on,Wednesday, ... how tobacco,companies take advantage of the lack of government ... aimed at hooking kids and,preventing current smokers from quitting. ...
... MIAMI, March 31 According to the World ... blacks, but,many Latinos and a few elderly Whites ... total incurable Glaucoma-Blindness,("White-Canes"). Most lack the opportunity to ... them of all their sight. Dr. Robert,Welsh, a ...
... highlights research on Blue Cross ... care utilization, EAGAN, Minn., March 31 In ... Quarterly, Blue Cross and Blue,Shield of Minnesota (Blue Cross) ... percent fewer visits to the emergency room and,had an ...
... 17,000 people with coronary artery disease or diabetes , , ... ACE inhibitor drug was as effective in reducing deaths, ... patients as a newer and more expensive angiotensin-receptor blocker ... The study of more than 17,000 people with coronary ...
... (Baltimore, MD) On April 2, the Kennedy Krieger ... Awareness Month with the one-year anniversary of the Interactive ... Launched in April 2007 by the Kennedy Krieger Institute, ... of causes, treatments, and the search for a possible ...
... Those Living with Epilepsy, TITUSVILLE, N.J., March 31 ... It has the ability to relay our deepest feelings ... strokes. For people,with epilepsy, art can be a valuable ... serious neurological condition., The sixth annual Expressions of ...
Cached Medicine News:Health News:Ohio Faith Leaders Call on Sen. Voinovich to Cosponsor Legislation to Protect Kids From Tobacco 2Health News:New Welsh 'Self-Test' to Cure Glaucoma, the Leading Cause of Preventable Blindness 2Health News:Blue Cross' Consumer-directed Health Plan - Options Blue - Members Not Sacrificing Health for the Sake of Saving Money 2Health News:Blue Cross' Consumer-directed Health Plan - Options Blue - Members Not Sacrificing Health for the Sake of Saving Money 3Health News:ACE Inhibitor as Effective as More Expensive Blood Pressure Drug 2Health News:First national autism registry shows notable impact on autism research in opening year 2Health News:People with Epilepsy Encouraged to Submit Artwork as Part of National Expressions of Courage(R) Art Contest 2Health News:People with Epilepsy Encouraged to Submit Artwork as Part of National Expressions of Courage(R) Art Contest 3Health News:People with Epilepsy Encouraged to Submit Artwork as Part of National Expressions of Courage(R) Art Contest 4
Ahmed Glaucoma Valve (small size) with Pars Plana Clip ....
Ahmed Glaucoma Valve....
... biocompatibility is established. Provides a robust and ... correct positioning on the globe. Pressure Ridge ... when covered by Tenons tissue, acts as ... hypotony. The range of implants allows the ...
... Goldmann standard automatic or manual kinetic ... white/white, blue/yellow or red/white stimuli/background colors. ... classic 4-2 threshold strategy. Examination with ... (including 30-2, 24-2, and 10-2). Gray-scale/ ...
Medicine Products: